Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 107 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Pharmacyclics LLC. Clear all

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Not listed
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 192
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Glendale, Arizona + 162 more

Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions: Ibrutinib, MEDI4736; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Stanford, California + 8 more

Conditions: Lymphoma
Interventions: Ibrutinib, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 44
States / cities: Tucson, Arizona • Greenbrae, California • La Jolla, California + 41 more

Conditions: CoronaVirus Induced Disease-2019 (COVID-19)
Interventions: Ibrutinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more

Conditions: Chronic Graft Versus Host Disease
Interventions: Ibrutinib; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 20
States / cities: Duarte, California • San Diego, California • San Francisco, California + 17 more

Conditions: Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Interventions: Ibrutinib, DA-EPOCH-R, Lenalidomide; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Orange, California + 7 more

Conditions: Carcinoma, Renal Cell, Urogenital Neoplasms, Urologic Neoplasms, Kidney Neoplasms
Interventions: motexafin gadolinium; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: Ibrutinib, Carfilzomib, Phone Calls; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: Ibrutinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 32
States / cities: Gilbert, Arizona • Campbell, California • Duarte, California + 29 more

Conditions: Richter Syndrome
Interventions: Obinutuzumab, Ibrutinib, CHOP; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: B-Cell Lymphoma, B-Cell Leukemia
Interventions: PCI-32765; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Palo Alto, California • Chicago, Illinois • Bethesda, Maryland + 6 more

Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Secondary Myelodysplastic Syndrome
Interventions: Azacitidine, Ibrutinib; Drug
Lead sponsor: Brian Jonas; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 2 more

Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Venetoclax; Drug · Biological
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Fresno, California • Los Angeles, California • Sacramento, California + 1 more

Conditions: Neoplasm Metastasis, Brain Neoplasms
Interventions: Motexafin gadolinium; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more

Conditions: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic
Interventions: PCI-24781; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Chicago, Illinois • Lafayette, Indiana • Omaha, Nebraska + 1 more

Conditions: B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Interventions: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib, Cirmtuzumab (RDR) plus ibrutinib, Cirmtuzumab plus ibrutinib, Ibrutinib alone; Drug
Lead sponsor: Oncternal Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Duarte, California • La Jolla, California • Sacramento, California + 8 more

Conditions: Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
Interventions: PCI-27483, Gemcitabine; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Anaheim, California • Titusville, Florida + 13 more

Conditions: High Risk Smoldering Multiple Myeloma
Interventions: Ibrutinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia, Leukemia
Interventions: Ibrutinib, Fludarabine, Cyclophosphamide, Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 9
States / cities: Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida + 4 more

Conditions: Carcinoid Tumors, Pancreatic NET
Interventions: Ibrutinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Marginal Zone Lymphoma, B-cell Lymphoma
Interventions: ibrutinib; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 13
States / cities: Tucson, Arizona • Duarte, California • Santa Monica, California + 8 more

Conditions: Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Chlorambucil; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 8
States / cities: La Jolla, California • Fort Myers, Florida • West Palm Beach, Florida + 5 more

Conditions: Mantle-Cell Lymphoma
Interventions: Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 14
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more

Search by objective public record fields.

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)